503B Outsourcing Facilities and Retatrutide: What Federal Law Requires
Bottom line: No 503B outsourcing facility may legally compound retatrutide. Section 503B requires the substance to appear on the FDA-approved bulk drug substance list. Retatrutide does not appear on that list.
What Is a 503B Outsourcing Facility?
Section 503B of the FD&C Act, added by the Drug Quality and Security Act (DQSA) of 2013, created a new category of compounding entity: the outsourcing facility. Unlike 503A pharmacies, 503B outsourcing facilities may compound drugs without patient-specific prescriptions and may distribute to healthcare facilities in advance of need. In exchange, they must register with the FDA and comply with Current Good Manufacturing Practice (CGMP) regulations.
503B outsourcing facilities are often perceived as more legitimate than 503A pharmacies because of their FDA registration and CGMP compliance requirements. However, this regulatory rigor does not expand the list of substances they may compound. The bulk drug substance list requirement is a separate and independent constraint.
The 503B Bulk Drug Substance List
For a 503B outsourcing facility to lawfully compound a drug from bulk, the bulk drug substance must appear on the FDA-approved bulk drug substance list — a list of substances the FDA has evaluated and determined may be used in outsourcing facility compounding. This list is distinct from the shortage list used in 503A compounding.
The FDA evaluates nominations to the bulk drug substance list based on clinical need, the availability of approved alternatives, and other factors. Substances not on the list may not be used in 503B compounding, regardless of the facility's CGMP compliance or FDA registration status.
Retatrutide does not appear on the 503B bulk drug substance list. It has not been nominated, evaluated, or approved for inclusion. A 503B outsourcing facility that compounds retatrutide is violating federal law, regardless of its registration status or quality systems.
Why 503B Compounding of Retatrutide Is Not Permitted
The controlling legal requirement for 503B bulk compounding is appearance on the FDA bulk drug substance list. Retatrutide does not appear on that list. No amount of CGMP compliance, FDA registration, or quality documentation changes this fact.
Some 503B facilities have argued that their quality systems and FDA oversight make their compounding inherently safer and therefore permissible. This argument conflates quality standards with legal authorization. The bulk drug substance list requirement is a statutory constraint, not a quality threshold. Meeting quality standards does not create legal authority to compound a substance not on the list.
The 503B framework was designed to improve the safety of compounded drugs, not to expand the universe of drugs that may be compounded. A 503B facility that compounds retatrutide is not operating in a gray area — it is operating outside the law, regardless of its quality systems.
503A vs. 503B: Side-by-Side Comparison for Retatrutide
| Attribute | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Regulatory framework | Section 503A, FD&C Act | Section 503B, FD&C Act (DQSA 2013) |
| FDA registration required | No | Yes |
| CGMP compliance required | No | Yes |
| Patient-specific prescription required | Yes | No (may distribute in advance) |
| Key legal requirement for retatrutide | Approved NDA or shortage-list status | Appearance on 503B bulk drug substance list |
| Does retatrutide qualify? | No — no NDA, not on shortage list | No — not on bulk drug substance list |
| Result | Compounding prohibited | Compounding prohibited |
FDA Enforcement Against Unlawful 503B Compounding
The FDA has taken enforcement action against 503B outsourcing facilities that compound substances not on the bulk drug substance list. Warning letters, product seizures, and consent decrees have been issued. The agency has specifically flagged unapproved GLP-1 peptides as a priority enforcement area, and 503B facilities are not exempt from this scrutiny.
Healthcare facilities that purchase compounded retatrutide from a 503B outsourcing facility are also at risk. Administering an unlawfully compounded drug exposes the facility and its practitioners to regulatory and liability consequences. The fact that the product came from a registered, CGMP-compliant facility does not provide legal cover if the substance itself was not authorized for compounding.
The only legal way to access retatrutide
Authorized clinical trials provide pharmaceutical-grade retatrutide at no cost, under medical supervision, at licensed research sites. No compounding facility can offer this.
How to find a legitimate retatrutide clinical trial →Frequently Asked Questions
Can a 503B outsourcing facility legally compound retatrutide?
No. Section 503B of the FD&C Act requires that any bulk drug substance used in compounding appear on the FDA-approved bulk drug substance list. Retatrutide does not appear on that list. Compounding it at a 503B facility violates federal law.
Does 503B CGMP compliance allow a facility to compound any drug?
No. CGMP compliance is a quality standard, not a legal authorization to compound any substance. A 503B facility must still comply with the bulk drug substance list requirement. Regulatory compliance in one dimension does not override a statutory prohibition in another.
Is the 503B bulk drug substance list the same as the shortage list?
No. These are separate lists with different legal functions. The shortage list (used in 503A) applies to finished drug products. The 503B bulk drug substance list applies to raw bulk substances. A drug can appear on one without appearing on the other. Retatrutide appears on neither.
Could a 503B facility compound retatrutide if it were placed on the shortage list?
No. The shortage list does not authorize 503B bulk compounding. Even if retatrutide were placed on a shortage list, that would not authorize 503B facilities to compound it from bulk. The 503B bulk drug substance list is the only relevant authorization for 503B bulk compounding.
What is the difference between 503A and 503B compounding for retatrutide?
Both frameworks prohibit compounding retatrutide, but for different reasons. 503A requires an approved NDA or shortage-list status (retatrutide has neither). 503B requires the substance to appear on the bulk drug substance list (retatrutide does not). The result is the same: no legal compounding pathway exists.
What is the only legal way to access retatrutide today?
Through an authorized clinical trial registered on ClinicalTrials.gov. Participants receive pharmaceutical-grade retatrutide at no cost under medical supervision at licensed research sites.